JP2015503540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015503540A5 JP2015503540A5 JP2014549478A JP2014549478A JP2015503540A5 JP 2015503540 A5 JP2015503540 A5 JP 2015503540A5 JP 2014549478 A JP2014549478 A JP 2014549478A JP 2014549478 A JP2014549478 A JP 2014549478A JP 2015503540 A5 JP2015503540 A5 JP 2015503540A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- cycloalkyl
- heterocyclyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- -1 aryl-C 1-3 -alkyl Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003386 piperidinyl group Chemical group 0.000 claims 5
- 125000004452 carbocyclyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 3
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000002757 morpholinyl group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003838 furazanyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000003566 oxetanyl group Chemical group 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000006587 (C5-C10) heteroarylene group Chemical group 0.000 claims 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 claims 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 claims 1
- 108010018763 Biotin carboxylase Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000000732 arylene group Chemical group 0.000 claims 1
- 125000005605 benzo group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000005551 pyridylene group Chemical group 0.000 claims 1
- 125000005576 pyrimidinylene group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11196046 | 2011-12-29 | ||
| EP11196046.4 | 2011-12-29 | ||
| PCT/EP2012/077025 WO2013098373A1 (en) | 2011-12-29 | 2012-12-28 | New azetidine derivatives, pharmaceutical compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503540A JP2015503540A (ja) | 2015-02-02 |
| JP2015503540A5 true JP2015503540A5 (OSRAM) | 2016-02-18 |
| JP6130398B2 JP6130398B2 (ja) | 2017-05-17 |
Family
ID=47557123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549478A Active JP6130398B2 (ja) | 2011-12-29 | 2012-12-28 | 新規アゼチジン誘導体、その医薬組成物及び使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8530461B2 (OSRAM) |
| EP (1) | EP2797885B1 (OSRAM) |
| JP (1) | JP6130398B2 (OSRAM) |
| WO (1) | WO2013098373A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014061693A1 (ja) * | 2012-10-17 | 2014-04-24 | 塩野義製薬株式会社 | 新規非芳香族炭素環又は非芳香族複素環誘導体 |
| CN105530940A (zh) * | 2013-09-12 | 2016-04-27 | 辉瑞大药厂 | 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途 |
| JPWO2015056782A1 (ja) | 2013-10-17 | 2017-03-09 | 塩野義製薬株式会社 | 新規アルキレン誘導体 |
| WO2015096651A1 (en) | 2013-12-23 | 2015-07-02 | Merck Sharp & Dohme Corp. | Pyrimidone carboxamide compounds as pde2 inhibitors |
| JP6668253B2 (ja) * | 2014-11-26 | 2020-03-18 | 武田薬品工業株式会社 | 二環性化合物 |
| AU2016209321B2 (en) * | 2015-01-20 | 2019-05-09 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic compounds, compositions and method of using thereof |
| WO2016145614A1 (en) | 2015-03-17 | 2016-09-22 | Merck Sharp & Dohme Corp. | Triazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016154081A1 (en) | 2015-03-26 | 2016-09-29 | Merck Sharp & Dohme Corp. | Pyrazolyl pyrimidinone compounds as pde2 inhibitors |
| WO2016179059A1 (en) | 2015-05-05 | 2016-11-10 | Merck Sharp & Dohme Corp. | Heteroaryl-pyrimidinone compounds as pde2 inhibitors |
| WO2016183741A1 (en) | 2015-05-15 | 2016-11-24 | Merck Sharp & Dohme Corp. | Pyrimidinone amide compounds as pde2 inhibitors |
| WO2016191935A1 (en) | 2015-05-29 | 2016-12-08 | Merck Sharp & Dohme Corp. | 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| WO2016192083A1 (en) | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Dihydropyrazolopyrimidinone compounds as pde2 inhibitors |
| EP3313852B1 (en) | 2015-06-25 | 2021-01-20 | Merck Sharp & Dohme Corp. | Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors |
| WO2017000277A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Substituted triazolo bicycliccompounds as pde2 inhibitors |
| WO2017000276A1 (en) | 2015-07-01 | 2017-01-05 | Merck Sharp & Dohme Corp. | Bicyclic heterocyclic compounds as pde2 inhibitors |
| EP3402480B1 (en) | 2016-01-11 | 2021-03-24 | EpicentRx, Inc. | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone |
| US11970486B2 (en) | 2016-10-24 | 2024-04-30 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| AU2018205275B2 (en) | 2017-01-06 | 2024-05-02 | Janssen Pharmaceutica Nv | Methods for the treatment of neurological disorders |
| US11873298B2 (en) | 2017-10-24 | 2024-01-16 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| US11510901B2 (en) | 2018-01-08 | 2022-11-29 | Epicentrx, Inc. | Methods and compositions utilizing RRx-001 combination therapy for radioprotection |
| AU2019238326B2 (en) | 2018-03-23 | 2025-03-06 | Janssen Pharmaceutica Nv | Compounds and uses thereof |
| KR20220007845A (ko) | 2019-01-24 | 2022-01-19 | 유마니티 테라퓨틱스, 인크. | 화합물 및 이의 용도 |
| CN113480541B (zh) * | 2019-03-07 | 2022-09-02 | 湖南化工研究院有限公司 | 咪唑并吡啶化合物及其中间体的制备方法 |
| US20230078764A1 (en) * | 2019-03-22 | 2023-03-16 | Yumanity Therapeutics, Inc. | Compounds and uses thereof |
| EA202192047A1 (ru) | 2019-11-13 | 2021-12-08 | Юманити Терапьютикс, Инк. | Соединения и их применение |
| US20250134858A1 (en) * | 2022-02-10 | 2025-05-01 | Epicentrx, Inc. | Compositions and methods for treatment of nafld and nash and related dyslipidemias |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ534582A (en) | 2002-02-27 | 2006-03-31 | Pfizer Prod Inc | ACC inhibitors |
| WO2005116009A1 (en) * | 2004-05-18 | 2005-12-08 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| EP1924578B1 (en) | 2005-09-01 | 2013-11-06 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| DE102005055726A1 (de) * | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| AU2006331882A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists |
| CA2641734A1 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| JPWO2007119833A1 (ja) * | 2006-04-14 | 2009-08-27 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| CA2654792A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| AR064965A1 (es) * | 2007-01-26 | 2009-05-06 | Merck Frosst Canada Inc | Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| WO2010043052A1 (en) | 2008-10-17 | 2010-04-22 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| WO2010127212A1 (en) | 2009-04-30 | 2010-11-04 | Forest Laboratories Holdings Limited | Inhibitors of acetyl-coa carboxylase |
| NZ603777A (en) | 2010-04-27 | 2013-08-30 | Takeda Pharmaceutical | Bicyclic compound derivatives and their use as acc inhibitors. |
-
2012
- 2012-12-14 US US13/714,519 patent/US8530461B2/en active Active
- 2012-12-28 JP JP2014549478A patent/JP6130398B2/ja active Active
- 2012-12-28 EP EP12813885.6A patent/EP2797885B1/en not_active Not-in-force
- 2012-12-28 WO PCT/EP2012/077025 patent/WO2013098373A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015503540A5 (OSRAM) | ||
| JP2013545791A5 (OSRAM) | ||
| JP2010530431A5 (OSRAM) | ||
| EP1857457A3 (en) | Benzimidazole derivative and its use as AII receptor antagonist | |
| RU2014105624A (ru) | Соединения индазола, способ их применения и фармацевтическая композиция | |
| JP2016516043A5 (OSRAM) | ||
| JP2015506355A5 (OSRAM) | ||
| JP2008503533A5 (OSRAM) | ||
| JP2011504903A5 (OSRAM) | ||
| JP2014526501A5 (OSRAM) | ||
| JP2014530900A5 (OSRAM) | ||
| JP2008501760A5 (OSRAM) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2017114355A (ru) | Производные нафтиридина в качестве антагонистов альфа v бета 6 интегрина для лечения, в частности, фиброзных заболеваний | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2013149174A (ru) | Новое имидазооксазиновое соединение или его соль | |
| JP2010515715A5 (OSRAM) | ||
| JP2012512907A5 (OSRAM) | ||
| JP2006524222A5 (OSRAM) | ||
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| JP2013508279A5 (OSRAM) | ||
| JP2007530493A5 (OSRAM) | ||
| JP2017531678A5 (OSRAM) | ||
| JP2007532607A5 (OSRAM) | ||
| JP2018502101A5 (OSRAM) |